Pacific Biosciences of California, Inc. (PACB Quick QuotePACB - Free Report) , popularly known as PacBio, has been gaining from its continued product development. The optimism, led by strong fourth-quarter results, is expected to contribute further. However, concerns about long purchasing cycles persist.

In the last six-month period, this Zacks Rank #1 (Strong Buy) company’s shares have gained 7.8% against the 6.8% decline of the industry. The S&P 500 Composite has improved 1.9% in the said time frame.

The renowned global provider of sequencing systems has a market capitalization of $410.7 million. The company projects 11.1% growth for 2027 and expects to maintain its strong performance going forward. PacBio’s earnings surpassed the Zacks Consensus Estimate in all the trailing four quarters, delivering an average surprise of 27.7%.

Image Source: Zacks Investment Research

Factors Favoring PACB’s Growth

Sequencing Technologies Strengthen Market Leadership:PacBio differentiates itself in the genomics industry through its proprietary HiFi long-read sequencing, based on Single-Molecule Real-Time (SMRT) technology. This technology enables the high-accuracy, real-time detection of complex genomic structures, such as structural variations, haplotypes, and epigenetic modifications.

Per a report by Data Bridge Market Research, the global SMRT market size was valued at $2.88 billion in 2024 and is projected to reach $4.36 billion by 2032, at a CAGR of 5.3%. Additionally, PacBio has expanded its offerings by integrating Sequencing by Binding chemistry with the launch of its Onso system in 2022, a short-read platform delivering ≥90% of bases at Q40+ accuracy, 15 times more precise than traditional sequencing methods. By providing both long-read and short-read technologies, PacBio uniquely serves diverse research and clinical applications while driving down costs and enhancing variant detection.

Robust Product Portfolio Driving Growth: PacBio’s fourth-quarter 2025 results reinforce the strength and expanding impact of its product portfolio, led by the Revio and Vega platforms, alongside a rapidly scaling consumables business. During the quarter, the company shipped 21 Revio systems and 42 Vega systems, bringing cumulative shipments to 331 Revio and 147 Vega instruments, reflecting improving placement momentum despite a still-challenging academic funding backdrop.

While Revio placements were pressured earlier in the year, fourth-quarter trends showed a clear recovery, with management highlighting stronger shipments and improving utilization per system. Importantly, around 20% of Revio orders in 2025 came from multisystem customers, signaling growing confidence among existing users to scale capacity — a key indicator of future consumables demand.

At the same time, approximately 65% of Vega placements were new-to-PacBio customers, underscoring the platform’s effectiveness in expanding the company’s installed base rather than simply upgrading existing users.

Strong Q4 Results: PacBio exited the fourth quarter of 2025 with better-than-expected results, where both earnings and revenues beat their respective Zacks Consensus Estimate. A robust increase in all the segmental revenues was encouraging. The expansion of the adjusted gross margin and reduction in total operating loss also bode well.

During the quarter, PacBio advanced its strategic focus on long-read sequencing through a series of clinical, research, and portfolio actions. The company joined the iHope initiative as the first long-read genomic sequencing partner, integrating HiFi sequencing into one of the world’s largest equitable rare-disease genomic testing networks, while also announcing collaborations with the n-Lorem Foundation and EspeRare to accelerate precision therapies for rare genetic diseases. HiFi sequencing was further validated with its adoption as a first-line approach for investigating sudden unexplained death in childhood.

On the technology front, PacBio expanded its multiomics capabilities with the launch of CiFi, a new long-read 3C method enabling chromosome-scale assemblies from a single SMRT Cell, developed in collaboration with UC Davis researchers.

A Factor That May Offset the Gains for PACB

Longer Purchasing Cycles: PacBio continues to face prolonged sales cycles for its high-cost Revio sequencing system, as customers navigate ongoing funding constraints and capital spending caution. Management highlighted that the academic and government funding environment remains challenging, particularly in the Americas, where uncertainty around grant timing and budget visibility continues to delay purchasing decisions. While Revio placements showed improvement sequentially in the fourth quarter, full-year instrument sales were still impacted by these pressures, reflecting muted capital equipment demand.

The company expects these challenges to persist into 2026, with management explicitly stating that it does not anticipate a meaningful recovery in academic funding or capital spending in the near term.

Estimate Trend

PacBio has been witnessing a positive estimate revision trend for 2026. Over the past 30 days, the Zacks Consensus Estimate for its adjusted loss per share has narrowed by 3 cents to 54 cents.

The Zacks Consensus Estimate for 2026 revenues is pegged at $175.4 million, indicating a 9.6% increase from the year-ago reported numbers.

Other Key Picks

Some other top-ranked stocks in the broader medical space are Intuitive Surgical (ISRG Quick QuoteISRG - Free Report) , Align Technology (ALGN Quick QuoteALGN - Free Report) and Cardinal Health (CAH Quick QuoteCAH - Free Report) .

Intuitive Surgical, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 15.7%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 13.24%. You can see the complete list of today’s Zacks #1 Rank stocks here.

Intuitive Surgical’s shares have gained 10.9% against the industry’s 6.8% decline over the past six months.

Align Technology, carrying a Zacks Rank #2 at present, has an estimated long-term growth rate of 10.1%. ALGN’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 6.16%.

ALGN’s shares have rallied 27.8% compared with the industry’s 16.7% growth over the past six months.

Cardinal Health, carrying a Zacks Rank of 2, has an estimated long-term growth rate of 15%. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 9.3%.

CAH’s shares have rallied 45% compared with the industry’s 16.7% growth over the past six months.